Kökenek Ünal Tuba Dilay, Kaplan Yilmaz Müzeyyen Burcu, Kandemir Olçay, Yora Samet, Taheri Serpil
Betul Ziya Eren Genome and Stem Cell Center, Erciyes University, Kayseri, Turkey.
Department of Pathology, Faculty of Medicine, Ankara Yildirim Beyazit University, Ankara, Turkey.
Medicine (Baltimore). 2025 Jun 27;104(26):e43077. doi: 10.1097/MD.0000000000043077.
Breast cancer is one of the most common cancers in women worldwide. Several therapy modalities have been created recently; however, resistance to therapy is a major issue. Cancer stem cell functions and regulations are important in tumor progression, invasion, metastasis, and therapy resistance. The expression levels of cancer stem cell genes CD44, CD24, and related miRNAs miR590-3p, miR599, and miR399-3p were aimed to be investigated before and after neoadjuvant therapy in breast cancer patients in this cross-sectional observational study. This study included 80 samples from 40 female patients. The expression of CD44 and CD24 genes and miR590-3p, miR599, and miR399-3p was analyzed by qPCR in pre- and posttreatment biopsies from breast carcinoma patients. Correlations between expression levels and other pathologic parameters, including molecular subtypes, grade, stage, metastasis, recurrence, pathologic response to therapy, and disease-free and overall survival, were investigated. CD44 and CD24 mRNA expression levels decreased significantly after treatment. However, miR590-3p expression increased after treatment. Patients with complete pathologic responses had upregulated CD24 and downregulated miR590-3p and miR399-3p levels in initial biopsies. Univariate analysis showed that increased expression levels of miR590-3p, miR599, and miR399-3p were significantly associated with shorter disease-free survival. A better understanding of the role of cancer stem cells in cancer can result in more promising results and patient-tailored therapy options. This study highlights the significant value of cancer stem cells and related miRNAs in response to therapy and recurrence.
乳腺癌是全球女性中最常见的癌症之一。近年来已出现多种治疗方式；然而，对治疗产生耐药性是一个主要问题。癌症干细胞的功能和调控在肿瘤进展、侵袭、转移及治疗耐药性方面起着重要作用。在这项横断面观察性研究中，旨在调查乳腺癌患者新辅助治疗前后癌症干细胞基因CD44、CD24以及相关微小RNA（miRNA）miR590 - 3p、miR599和miR399 - 3p的表达水平。本研究纳入了40名女性患者的80份样本。通过定量聚合酶链反应（qPCR）分析乳腺癌患者治疗前和治疗后活检样本中CD44和CD24基因以及miR590 - 3p、miR599和miR399 - 3p的表达。研究了表达水平与其他病理参数之间的相关性，包括分子亚型、分级、分期、转移、复发、对治疗的病理反应以及无病生存期和总生存期。治疗后CD44和CD24 mRNA表达水平显著下降。然而，miR590 - 3p的表达在治疗后升高。在初始活检中，具有完全病理反应的患者CD24上调，miR590 - 3p和miR399 - 3p水平下调。单因素分析显示，miR590 - 3p、miR599和miR399 - 3p表达水平升高与较短的无病生存期显著相关。更好地了解癌症干细胞在癌症中的作用可能会带来更有前景的结果和针对患者的治疗选择。本研究突出了癌症干细胞及相关miRNA在治疗反应和复发方面的重要价值。
